|
US5833975A
(en)
|
1989-03-08 |
1998-11-10 |
Virogenetics Corporation |
Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
|
|
DE69233158T2
(de)
|
1991-03-07 |
2004-05-13 |
Connaught Technology Corp., Greenville |
Gentechnologisch hergestellter stamm für impfstoffe
|
|
AU694519B2
(en)
|
1994-04-29 |
1998-07-23 |
Immuno Aktiengesellschaft |
Recombinant poxviruses with foreign polynucleotides in essential regions
|
|
US6093700A
(en)
|
1995-05-11 |
2000-07-25 |
Thomas Jefferson University |
Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF
|
|
JP3907698B2
(ja)
|
1994-10-03 |
2007-04-18 |
アメリカ合衆国 |
抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
|
|
UA68327C2
(en)
*
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
|
US6004777A
(en)
|
1997-03-12 |
1999-12-21 |
Virogenetics Corporation |
Vectors having enhanced expression, and methods of making and uses thereof
|
|
US20030044384A1
(en)
|
1997-10-09 |
2003-03-06 |
Pro-Virus, Inc. |
Treatment of neoplasms with viruses
|
|
WO2000073487A1
(en)
|
1999-05-27 |
2000-12-07 |
Arizona Board Of Regents |
Novel viral vectors having enhanced effectiveness with dramatically reduced virulence
|
|
CA2375189C
(en)
|
1999-05-28 |
2010-02-09 |
The Government Of The United States Of America |
A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
|
|
EP1955703A1
(en)
|
1999-11-12 |
2008-08-13 |
Oncolytics Biotech Inc. |
Viruses for the treatment of cellular proliferative disorders
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
JP2004513184A
(ja)
|
2000-11-20 |
2004-04-30 |
オンコリティクス バイオテック， インコーポレイティッド |
固形腫瘍塊への最適なウイルス送達法
|
|
PL212047B1
(pl)
|
2000-11-23 |
2012-08-31 |
Bavarian Nordic As |
Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania
|
|
US6372455B1
(en)
|
2001-04-19 |
2002-04-16 |
Arizona Board Of Regents |
Recombinant vaccinia viral vectors
|
|
US6750043B2
(en)
|
2001-04-19 |
2004-06-15 |
Arizona Board Of Regents |
Viral vectors having reduced virulence
|
|
US20040091995A1
(en)
|
2001-06-15 |
2004-05-13 |
Jeffrey Schlom |
Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
|
|
US20030113919A1
(en)
|
2001-08-17 |
2003-06-19 |
Aventis Pasteur, Ltd. |
Immunogenic targets for melanoma
|
|
DE10144664B4
(de)
*
|
2001-09-11 |
2005-06-09 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
|
|
US7001718B2
(en)
|
2001-12-20 |
2006-02-21 |
Massachusetts Institute Of Technology |
Method of inhibiting pathogenicity of infectious agents
|
|
NZ536592A
(en)
|
2002-04-19 |
2007-01-26 |
Bavarian Nordic As |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
US20070178065A1
(en)
|
2002-05-03 |
2007-08-02 |
Lattime Edmund C |
Neutralizing factors as vaccine adjuvants
|
|
DE10221411B4
(de)
|
2002-05-14 |
2004-07-08 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Rekombinantes Fowlpox-Virus
|
|
CN102703393A
(zh)
|
2002-05-16 |
2012-10-03 |
巴法里安诺迪克有限公司 |
表达插入痘病毒基因组中的同源基因的重组痘病毒
|
|
WO2004042001A2
(en)
|
2002-05-17 |
2004-05-21 |
Emory University |
Virus-like particles, methods of preparation, and immonogenic compositions
|
|
JP2004031674A
(ja)
|
2002-06-26 |
2004-01-29 |
Disco Abrasive Syst Ltd |
コンタミネーション除去装置
|
|
WO2004009763A2
(en)
|
2002-07-24 |
2004-01-29 |
Arizona Board Of Regents |
Use of vaccinia virus deleted for the e3l gene as a vaccine vector
|
|
AU2003267361A1
(en)
|
2002-09-12 |
2004-04-30 |
Gsf-Forschungszentrum Fur Umwelt Und Gesundheit Gmbh |
Orthopoxvirus antigens and use thereof
|
|
CA2511625A1
(en)
|
2002-12-23 |
2004-07-15 |
City Of Hope |
Modified vaccinia ankara expressing p53 in cancer immunotherapy
|
|
WO2004087047A2
(en)
|
2003-02-07 |
2004-10-14 |
Arizona Board Of Regents |
Mutants of replication competent vaccinia virus
|
|
DE602004015418D1
(de)
*
|
2003-02-18 |
2008-09-11 |
Helmholtz Zentrum Muenchen |
Rekombinantes mva und verfahren zur erzeugung davon
|
|
EP1644492B1
(en)
|
2003-06-18 |
2009-01-07 |
Genelux Corporation |
Modified recombinant vaccinia viruses, uses thereof
|
|
US20070036758A1
(en)
|
2003-07-08 |
2007-02-15 |
Bertram Jacobs |
Mutants of vaccinia virus as oncolytic agents
|
|
CA2436196A1
(en)
|
2003-07-25 |
2005-01-25 |
Oncolytics Biotech Inc. |
Oncolytic virus for purging cellular compositions of cells of lymphoid malignancies
|
|
CA2435967A1
(en)
|
2003-07-25 |
2005-01-25 |
Oncolytics Biotech, Inc. |
Reovirus for the treatment of lymphoid malignancies
|
|
WO2005028634A2
(en)
|
2003-09-18 |
2005-03-31 |
Emory University |
Improved mva vaccines
|
|
EP1518932A1
(en)
|
2003-09-29 |
2005-03-30 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Modified vaccinia virus Ankara (MVA) mutant and use thereof
|
|
EP2338524B1
(en)
|
2004-08-12 |
2013-05-22 |
Cedars-Sinai Medical Center |
Combined gene therapy for the treatment of macroscopic gliomas
|
|
EP1683870A1
(en)
|
2005-01-24 |
2006-07-26 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vaccines based on the use of MVA
|
|
WO2006120474A2
(en)
|
2005-05-13 |
2006-11-16 |
Oxxon Therapeutics Ltd |
Compositions for inducing an immune response against tumor antigens
|
|
ES2281252B1
(es)
|
2005-07-27 |
2009-02-16 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
US20070077231A1
(en)
|
2005-09-30 |
2007-04-05 |
Contag Christopher H |
Immune effector cells pre-infected with oncolytic virus
|
|
DK1989224T3
(da)
|
2006-02-24 |
2011-02-14 |
Us Gov Health & Human Serv |
Immunogene peptider og anvendelsesmetoder
|
|
KR100788930B1
(ko)
|
2006-04-18 |
2007-12-27 |
포항공과대학교 산학협력단 |
항암 조성물
|
|
DK2073837T3
(da)
|
2006-10-06 |
2014-09-29 |
Bavarian Nordic Inc |
Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer
|
|
EP2426142A3
(en)
|
2006-10-16 |
2012-06-13 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
WO2008108890A2
(en)
|
2006-10-18 |
2008-09-12 |
University Of Rochester |
Conditionally replicating viruses for cancer therapy
|
|
KR20080084528A
(ko)
|
2007-03-15 |
2008-09-19 |
제네렉스 바이오테라퓨틱스 인크. |
종양살상형 백시니아 바이러스 암 치료
|
|
JP5213075B2
(ja)
|
2007-06-15 |
2013-06-19 |
ジェネラックス・コーポレイション |
腫瘍の画像化および／または処置のための微生物
|
|
WO2009011924A1
(en)
|
2007-07-18 |
2009-01-22 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
|
NZ601827A
(en)
|
2007-10-18 |
2014-01-31 |
Bavarian Nordic Inc |
Use of mva to treat prostate cancer
|
|
EP2211880A4
(en)
|
2007-10-22 |
2012-11-14 |
Oncolytics Biotech Inc |
TREATMENT PROCEDURE FOR PROLIFERATIVE DISEASES
|
|
CA2705869C
(en)
|
2007-11-19 |
2012-10-30 |
Philippe Erbs |
Poxviral oncolytic vectors
|
|
KR101542275B1
(ko)
|
2007-11-19 |
2015-08-06 |
트랜스진 에스.에이. |
폭스바이러스성 온콜리틱 벡터
|
|
WO2009139921A2
(en)
|
2008-05-16 |
2009-11-19 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
US20110142874A1
(en)
|
2008-06-09 |
2011-06-16 |
Arizona Board Of Regents |
Compositions, Methods, and Kits for Eliciting an Immune Response
|
|
JP2012500229A
(ja)
|
2008-08-21 |
2012-01-05 |
オタワ ホスピタル リサーチ インスティチュート |
遺伝子操作された相乗的腫瘍溶解性ウイルス共生
|
|
WO2010127115A1
(en)
|
2009-04-30 |
2010-11-04 |
Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) |
Modified immunization vectors
|
|
CA2709292A1
(en)
|
2009-07-10 |
2011-01-10 |
The Governors Of The University Of Alberta |
Oncolytic viruses and methods for treating neoplastic disorders
|
|
BR112012005774B8
(pt)
|
2009-09-14 |
2023-02-14 |
Jennerex Inc |
uso de um inibidor de quinase antiangiogênico no tratamento de câncer
|
|
GB201006405D0
(en)
|
2010-04-16 |
2010-06-02 |
Isis Innovation |
Poxvirus expression system
|
|
WO2011156470A1
(en)
|
2010-06-08 |
2011-12-15 |
Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University |
A method for inserting genetic material into genomic dna
|
|
US20130230884A1
(en)
|
2010-07-16 |
2013-09-05 |
John Chaput |
Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation
|
|
WO2012040474A2
(en)
|
2010-09-23 |
2012-03-29 |
Baxter International Inc. |
Recombinant viral vectors and methods for inducing an immune response to yellow fever virus
|
|
KR101942237B1
(ko)
|
2011-01-04 |
2019-01-25 |
신라젠(주) |
종양 항원에 대한 항체의 생산 및 종양용해 우두 바이러스의 투여에 의한 종양 특이적 보체 의존적 세포독성의 생산
|
|
CN114262690A
(zh)
|
2011-04-15 |
2022-04-01 |
吉恩勒克斯公司 |
减毒的痘苗病毒的克隆毒株及其使用方法
|
|
FI20115914A7
(fi)
|
2011-09-16 |
2013-03-17 |
Oncos Therapeutics Ltd |
Muunnettu onkolyyttinen virus
|
|
US8859256B2
(en)
|
2011-10-05 |
2014-10-14 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
WO2013063348A1
(en)
|
2011-10-28 |
2013-05-02 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Genetic element that enhances protein translation
|
|
WO2013138522A2
(en)
|
2012-03-16 |
2013-09-19 |
Genelux Corporation |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
WO2014031693A1
(en)
|
2012-08-20 |
2014-02-27 |
Genelux Corporation |
Compositions containing protein polymers and vaccinia virus, and methods of use thereof
|
|
JP6457940B2
(ja)
|
2012-08-30 |
2019-01-23 |
アムジエン・インコーポレーテツド |
単純ヘルペスウイルスおよび免疫チェックポイント阻害薬を使用して、メラノーマを治療するための方法
|
|
WO2014037124A1
(en)
|
2012-09-04 |
2014-03-13 |
Bavarian Nordic A/S |
Methods and compositions for enhancing vaccine immune responses
|
|
US20150250837A1
(en)
|
2012-09-20 |
2015-09-10 |
Morningside Technology Ventures Ltd. |
Oncolytic virus encoding pd-1 binding agents and uses of the same
|
|
TWI690322B
(zh)
|
2012-10-02 |
2020-04-11 |
法商傳斯堅公司 |
含病毒的調配物及其使用
|
|
US20150283220A1
(en)
|
2012-10-19 |
2015-10-08 |
Bavarian Nordic, Inc. |
Methods and compositions for the treatment of cancer
|
|
US20180200320A1
(en)
|
2012-11-21 |
2018-07-19 |
Aviratek Biomedical Solutions, Llc |
Method and compositions for the use of botanical extracts in the treatment of viral infections, cancer, pain, itch, and inflammation
|
|
US20140193859A1
(en)
|
2013-01-08 |
2014-07-10 |
Bertram Jacobs |
Temperature-dependent insertion of genetic material into genomic DNA
|
|
US20140271549A1
(en)
|
2013-03-15 |
2014-09-18 |
Aladar A. Szalay |
Use of Antibiotics to Enhance Treatment With Therapeutic Viruses
|
|
WO2014193973A2
(en)
|
2013-05-28 |
2014-12-04 |
Dcb-Usa Llc |
Antibody locker for the inactivation of protein drug
|
|
GB201310917D0
(en)
|
2013-06-19 |
2013-07-31 |
Cancer Res Inst Royal |
Vaccinia virus for gene-directed enzyme prodrug therapy
|
|
DK3036329T3
(da)
|
2013-08-22 |
2021-01-11 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Immunonkolytiske terapier
|
|
WO2015066715A1
(en)
|
2013-11-04 |
2015-05-07 |
Viracell Advanced Products, Llc |
Virus-like particles and methods related thereto
|
|
WO2015069571A1
(en)
|
2013-11-05 |
2015-05-14 |
Bavarian Nordic, Inc. |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
|
|
WO2015084897A2
(en)
|
2013-12-02 |
2015-06-11 |
Mirimmune, Llc |
Immunotherapy of cancer
|
|
EP3082853A2
(en)
|
2013-12-20 |
2016-10-26 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
|
US20170106065A1
(en)
|
2013-12-31 |
2017-04-20 |
Bavarian Nordic A/S |
Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
|
|
WO2015138471A1
(en)
|
2014-03-10 |
2015-09-17 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Heat inactivated poxvirus improves vaccination results
|
|
WO2015138741A1
(en)
|
2014-03-12 |
2015-09-17 |
Cars-N-Kids Llc |
Systems and methods for determining if a child safety seat is in a moving vehicle
|
|
GB201405834D0
(en)
|
2014-04-01 |
2014-05-14 |
Univ London Queen Mary |
Oncolytic virus
|
|
EP3142690B1
(en)
|
2014-05-13 |
2022-02-23 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
|
|
AU2015289081B2
(en)
|
2014-07-16 |
2020-02-06 |
Transgene Sa |
Combination of oncolytic virus with immune checkpoint modulators
|
|
DK3169341T3
(da)
|
2014-07-16 |
2019-08-05 |
Transgene Sa |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
US10512684B2
(en)
|
2014-09-26 |
2019-12-24 |
Bavarian Nordic A/S |
Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin
|
|
KR101645642B1
(ko)
|
2014-10-16 |
2016-08-11 |
대한민국 |
Kvac１０３ 유래의 재조합 백시니아 바이러스
|
|
ES3011733T3
(en)
|
2015-02-13 |
2025-04-08 |
Transgene |
Immunotherapeutic vaccine and antibody combination therapy
|
|
EP4122492A1
(en)
|
2015-02-25 |
2023-01-25 |
Memorial Sloan Kettering Cancer Center |
Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
|
|
KR20180006916A
(ko)
*
|
2015-04-17 |
2018-01-19 |
메모리얼 슬로안-케터링 캔서 센터 |
고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
|
|
EP3307330B1
(en)
|
2015-06-15 |
2021-03-10 |
New York University |
Method of treatment using oncolytic viruses
|
|
CN108025056B
(zh)
|
2015-06-19 |
2022-01-14 |
新罗杰股份有限公司 |
用于病毒栓塞的组合物和方法
|
|
CN105039269A
(zh)
|
2015-07-24 |
2015-11-11 |
北京鼎成肽源生物技术有限公司 |
一种用于治疗非小细胞肺癌的新型病毒疫苗及其制备方法
|
|
EP4137150A1
(en)
|
2015-08-03 |
2023-02-22 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use
|
|
HK1255192A1
(zh)
|
2015-09-08 |
2019-08-09 |
Sillajen, Inc. |
表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法
|
|
EP3347473A4
(en)
|
2015-09-09 |
2019-04-10 |
Tvax Biomedical I, LLC |
METHOD FOR COMBINING ADOPTIVE T CELL THERAPY WITH ONCOLYTIC VIRUS ATTACHMENT THERAPY
|
|
JP7171433B2
(ja)
|
2015-10-30 |
2022-11-15 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Ｈｅｒ－２発現固形腫瘍の処置のための組成物および方法
|
|
EA201891022A1
(ru)
|
2015-12-17 |
2019-01-31 |
Псайоксус Терапьютикс Лимитед |
Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
|
|
US10881725B2
(en)
|
2016-01-29 |
2021-01-05 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine
|
|
CN109152827B
(zh)
|
2016-02-25 |
2023-07-21 |
纪念斯隆凯特琳癌症中心 |
重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
|
|
JP7025339B2
(ja)
|
2016-02-25 |
2022-02-24 |
メモリアル スローン ケタリング キャンサー センター |
癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
|
|
PL3426271T3
(pl)
|
2016-03-10 |
2025-11-24 |
Cg Oncology, Inc. |
Sposoby leczenia guzów litych terapią skojarzoną
|
|
US10842835B2
(en)
|
2016-05-25 |
2020-11-24 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Oncolytic vaccinia virus mutants and using same for cancer treatment
|
|
US10888594B2
(en)
|
2016-05-30 |
2021-01-12 |
National University Corporation Tottori University |
Genetically engineered vaccinia viruses
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
JP7312695B2
(ja)
|
2016-07-19 |
2023-07-21 |
ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
Ｓｔａｔ３を標的とする腫瘍溶解性ウイルス
|
|
KR102190326B1
(ko)
|
2016-07-21 |
2020-12-11 |
코오롱생명과학 주식회사 |
재조합 백시니아 바이러스 및 이의 용도
|
|
WO2018031694A1
(en)
|
2016-08-09 |
2018-02-15 |
City Of Hope |
Chimeric poxvirus compositions and uses thereof
|
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
|
CN110022867A
(zh)
|
2016-09-21 |
2019-07-16 |
斯蒂芬·H·索恩 |
高迁移率族蛋白box i突变体
|
|
US20200046784A1
(en)
|
2016-09-30 |
2020-02-13 |
University Health Network |
Recombinant oncolytic viruses for cancer therapy
|
|
BR112021004692A2
(pt)
|
2018-09-15 |
2021-06-08 |
Memorial Sloan Kettering Cancer Center |
poxvírus recombinantes para imunoterapia de câncer
|